EP PerMed grant awarded to European consortium led by Sigrid S. Skånland at Institute for Cancer Research
A European consortium coordinated by Sigrid S. Skånland, project group leader at the Department of Cancer Immunology, has been awarded an EP PerMed grant co-funded by the European Commission for their project “Chronic lymphocytic leukemia: Improving survival and quality of life (CLL-OUTCOME)”.
The vision of the European Partnership for Personalised Medicine is to “improve health outcomes within sustainable healthcare systems through research, development, innovation and implementation of personalised medicine approaches for the benefit of patients, citizens, and society”.
The CLL-OUTCOME project aims to improve survival and health related quality of life for patients with chronic lymphocytic leukemia. Specifically, to increase treatment efficacy of targeted therapies and to reduce adverse events.
“Our multidisciplinary consortium has previously identified biomarkers for predicting clinical outcomes and developed a novel machine learning-based prognostic model based on these biomarkers as a clinical decision support tool in the ERA PerMed project CLL-CLUE. In CLL-OUTCOME, we will validate this prognostic model in a feasibility study using samples and data from clinical studies,” says Skånland. “This extended collaboration provides a unique opportunity to move efficiently from discovery towards implementation, to the benefit of the patients.”
CLL-OUTCOME will be carried out as a collaborative effort including clinical, molecular, computational, and health economic research groups in chronic lymphocytic leukemia in Europe.
The CLL-OUTCOME consortium:
Coordinator:
Sigrid S. Skånland (Oslo University Hospital, Norway)
Partners:
Tero Aittokallio (University of Helsinki, Finland)
Barbara Eichhorst (University Hospital of Cologne, Germany)
Olav Ljøsne (The Norwegian Blood Cancer Association, Norway)
Carin Uyl-de Groot (Erasmus University Rotterdam, The Netherlands)
Carsten Utoft Niemann (Copenhagen University Hospital, Denmark)
Thorsten Zenz (University of Zurich, Switzerland)
The project is funded with 1.5 million Euro and will run over three years.
Links:
About EP PerMed
The ERA PerMed project CLL-CLUE
Department of Cancer Immunology
Sigrid Skånland’s project group: Functional precision medicine for hematologic cancers